KR102374499B1 - Nafld 및 nash 의 치료 - Google Patents

Nafld 및 nash 의 치료 Download PDF

Info

Publication number
KR102374499B1
KR102374499B1 KR1020167031356A KR20167031356A KR102374499B1 KR 102374499 B1 KR102374499 B1 KR 102374499B1 KR 1020167031356 A KR1020167031356 A KR 1020167031356A KR 20167031356 A KR20167031356 A KR 20167031356A KR 102374499 B1 KR102374499 B1 KR 102374499B1
Authority
KR
South Korea
Prior art keywords
nash
nafld
mbx
liver
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167031356A
Other languages
English (en)
Korean (ko)
Other versions
KR20160136451A (ko
Inventor
브라이언 로버츠
쉬에얀 왕
윤정 최
데이비드 카프
로버트 마틴
찰스 에이 맥위어터
Original Assignee
사이머베이 쎄라퓨틱스, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53373532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102374499(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 사이머베이 쎄라퓨틱스, 인코퍼레이티드 filed Critical 사이머베이 쎄라퓨틱스, 인코퍼레이티드
Publication of KR20160136451A publication Critical patent/KR20160136451A/ko
Application granted granted Critical
Publication of KR102374499B1 publication Critical patent/KR102374499B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
KR1020167031356A 2014-04-11 2015-04-10 Nafld 및 nash 의 치료 Active KR102374499B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461978335P 2014-04-11 2014-04-11
US61/978,335 2014-04-11
PCT/US2015/025416 WO2015157697A1 (en) 2014-04-11 2015-04-10 Treatment of nafld and nash

Publications (2)

Publication Number Publication Date
KR20160136451A KR20160136451A (ko) 2016-11-29
KR102374499B1 true KR102374499B1 (ko) 2022-03-14

Family

ID=53373532

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167031356A Active KR102374499B1 (ko) 2014-04-11 2015-04-10 Nafld 및 nash 의 치료

Country Status (27)

Country Link
US (7) US9381181B2 (enExample)
EP (1) EP3129018B1 (enExample)
JP (1) JP6865038B2 (enExample)
KR (1) KR102374499B1 (enExample)
CN (1) CN106163508A (enExample)
AU (1) AU2015243239B2 (enExample)
BR (1) BR112016023269A8 (enExample)
CA (1) CA2944139C (enExample)
CL (1) CL2016002517A1 (enExample)
CY (1) CY1122602T1 (enExample)
DK (1) DK3129018T3 (enExample)
EA (1) EA036704B1 (enExample)
ES (1) ES2764467T3 (enExample)
HR (1) HRP20192299T1 (enExample)
IL (1) IL248193B (enExample)
LT (1) LT3129018T (enExample)
MX (1) MX369921B (enExample)
NZ (1) NZ724740A (enExample)
PH (1) PH12016501978B1 (enExample)
PL (1) PL3129018T3 (enExample)
PT (1) PT3129018T (enExample)
RS (1) RS59637B1 (enExample)
SG (1) SG11201608077PA (enExample)
SI (1) SI3129018T1 (enExample)
SM (1) SMT202000019T1 (enExample)
UA (1) UA121208C2 (enExample)
WO (1) WO2015157697A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028067A1 (en) 2008-09-02 2010-03-11 Amarin Corporation Plc Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
MX2011004077A (es) 2008-10-17 2011-08-17 Metabolex Inc Metodos para reducir particulas de ldl densas, pequeñas.
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SMT201800047T1 (it) 2009-04-29 2018-03-08 Amarin Pharmaceuticals Ie Ltd Composizione farmaceutica stabile e metodi di utilizzo della stessa
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
BR122019016628B8 (pt) 2009-09-23 2021-07-27 Amarin Corp Plc uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
UA128280C2 (uk) 2012-06-29 2024-05-29 Амарін Фармасьютікалз Айрленд Лімітед Спосіб зменшення ризику розвитку серцево-судинної події у суб'єкта, що одержує терапію статином
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
HUE041733T2 (hu) 2014-03-20 2019-05-28 Cymabay Therapeutics Inc Intrahepatikus kolesztázisos betegségek kezelése
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
WO2015157697A1 (en) 2014-04-11 2015-10-15 Cymabay Therapeutics, Inc. Treatment of nafld and nash
EP3149156B1 (en) 2014-05-28 2021-02-17 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US11584916B2 (en) 2014-10-17 2023-02-21 Children's Hospital Medical Center Method of making in vivo human small intestine organoids from pluripotent stem cells
KR20170131644A (ko) * 2015-03-26 2017-11-29 티3디 테라퓨틱스, 인크. 인단 아세트산 유도체를 사용한 간 질환의 치료 방법
CN115025079A (zh) 2015-04-28 2022-09-09 普罗诺瓦生物医药挪威公司 结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途
WO2017049157A1 (en) * 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
WO2017139708A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
CN116790476A (zh) 2016-05-05 2023-09-22 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
GB201614455D0 (en) * 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
KR102546194B1 (ko) 2016-11-04 2023-06-21 칠드런즈 호스피탈 메디칼 센터 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
US10493363B2 (en) * 2016-11-09 2019-12-03 Activision Publishing, Inc. Reality-based video game elements
KR102558606B1 (ko) 2016-12-05 2023-07-26 칠드런즈 호스피탈 메디칼 센터 결장 유사장기 및 이를 제조 및 사용하는 방법
WO2018191673A1 (en) 2017-04-14 2018-10-18 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
WO2018204775A1 (en) 2017-05-05 2018-11-08 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US20190076500A1 (en) 2017-09-13 2019-03-14 Novartis Ag Combinations comprising fxr agonists
EP3694603A4 (en) 2017-10-10 2021-07-14 Children's Hospital Medical Center ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF
JP6976030B2 (ja) * 2017-10-27 2021-12-01 サムヤン コーポレイション 非アルコール性脂肪肝疾患の予防または改善用組成物
CA3084728A1 (en) 2017-12-06 2019-06-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
JP7506657B2 (ja) 2018-07-26 2024-06-26 チルドレンズ ホスピタル メディカル センター 肝胆膵組織およびその作製方法
US12428622B2 (en) 2018-09-12 2025-09-30 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
ES2983568T3 (es) 2018-09-24 2024-10-23 Amarin Pharmaceuticals Ie Ltd Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto
CA3118965A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
BR112021009038A2 (pt) * 2018-11-16 2021-08-10 Cymabay Therapeutics, Inc. tratamento combinado de nafld e nash
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
JP7610533B2 (ja) 2019-05-31 2025-01-08 チルドレンズ ホスピタル メディカル センター 造血幹細胞の生成および拡大方法
EP4028008A4 (en) 2019-09-12 2023-09-13 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EP4058141A4 (en) 2019-11-12 2023-11-22 Amarin Pharmaceuticals Ireland Limited METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH Atrial fibrillation and/or atrial flutter
US20210145774A1 (en) * 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
WO2021097034A1 (en) * 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
KR20230024277A (ko) * 2020-05-13 2023-02-20 테른스 파마슈티칼스, 인크. 간 장애의 조합 치료
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
EP4337184A1 (en) * 2021-05-11 2024-03-20 Genfit Ppar-agonists for use in the treatment of liver failure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6222025B1 (en) 1995-03-06 2001-04-24 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
CA2749312A1 (en) 1996-02-14 1997-08-21 Novartis Ag Sugar-modified gapped oligonucleotides
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
CA2539446C (en) 2003-09-19 2013-12-03 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
DK1725234T4 (en) 2004-03-05 2016-05-09 Univ Pennsylvania METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
MX2011004077A (es) 2008-10-17 2011-08-17 Metabolex Inc Metodos para reducir particulas de ldl densas, pequeñas.
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2015077154A1 (en) 2013-11-20 2015-05-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
HUE041733T2 (hu) 2014-03-20 2019-05-28 Cymabay Therapeutics Inc Intrahepatikus kolesztázisos betegségek kezelése
WO2015157697A1 (en) 2014-04-11 2015-10-15 Cymabay Therapeutics, Inc. Treatment of nafld and nash
CN106470675A (zh) 2014-06-26 2017-03-01 西玛贝医药公司 严重高甘油三酯血症的治疗

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EXPERT OPINION ON PHARMACOTHERAPY, vol.15, no.4, pages 493~503*
J Clin Endocrinol Metab. 96, 2889~2897, 2011*

Also Published As

Publication number Publication date
US20180008566A1 (en) 2018-01-11
PH12016501978B1 (en) 2023-07-12
NZ724740A (en) 2019-11-29
US10342770B2 (en) 2019-07-09
JP2017513836A (ja) 2017-06-01
CA2944139C (en) 2020-11-03
PT3129018T (pt) 2020-01-15
US20200009092A1 (en) 2020-01-09
US20160324812A1 (en) 2016-11-10
US20210038546A1 (en) 2021-02-11
PL3129018T3 (pl) 2020-05-18
MX369921B (es) 2019-11-26
HRP20192299T1 (hr) 2020-03-06
EA201692050A1 (ru) 2017-01-30
CN106163508A (zh) 2016-11-23
US11179359B2 (en) 2021-11-23
US20150290154A1 (en) 2015-10-15
EP3129018B1 (en) 2019-10-23
SI3129018T1 (sl) 2020-02-28
CY1122602T1 (el) 2021-03-12
CL2016002517A1 (es) 2017-05-05
US9381181B2 (en) 2016-07-05
US10188620B2 (en) 2019-01-29
IL248193B (en) 2019-03-31
AU2015243239B2 (en) 2019-11-14
EA036704B1 (ru) 2020-12-10
RS59637B1 (sr) 2020-01-31
US9616039B2 (en) 2017-04-11
ES2764467T3 (es) 2020-06-03
LT3129018T (lt) 2020-01-10
SMT202000019T1 (it) 2020-03-13
WO2015157697A1 (en) 2015-10-15
US20180228752A1 (en) 2018-08-16
AU2015243239A1 (en) 2016-10-20
BR112016023269A8 (pt) 2021-06-29
CA2944139A1 (en) 2015-10-15
SG11201608077PA (en) 2016-10-28
EP3129018A1 (en) 2017-02-15
UA121208C2 (uk) 2020-04-27
DK3129018T3 (da) 2020-01-20
BR112016023269A2 (pt) 2017-08-15
MX2016013375A (es) 2017-02-15
JP6865038B2 (ja) 2021-04-28
US20190142776A1 (en) 2019-05-16
US9962346B2 (en) 2018-05-08
US10722483B2 (en) 2020-07-28
KR20160136451A (ko) 2016-11-29
PH12016501978A1 (en) 2016-12-19

Similar Documents

Publication Publication Date Title
US11179359B2 (en) Treatment of NAFLD and NASH
CA3118961A1 (en) Combination treatment of nafld and nash
JP6568577B2 (ja) 肝内胆汁うっ滞症の治療
WO2020102351A1 (en) Treatment of obesity and its complications
CN110876751B (zh) 曲美替尼在制备预防和/或治疗非酒精性肝炎和/或非酒精性脂肪性肝病中的应用
KR102408288B1 (ko) 간내 담즙 정체성 질환의 치료
HK1228275A1 (en) Treatment of nafld and nash
HK1228275B (en) Treatment of nafld and nash

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000